• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tvardi Therapeutics Inc.

    4/1/26 6:10:39 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVRD alert in real time by email
    S-8 1 tm2610047d3_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on April 1, 2026

     

    Registration No. 333    

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Tvardi Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

         
    Delaware   75-3175693

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

       

    3 Sugar Creek Ctr. Blvd.

    Suite 525

    Sugar Land, Texas

      77478
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    2025 Equity Incentive Plan

    2025 Employee Stock Purchase Plan

    (Full titles of the plans)

     

     

    Imran Alibhai, Ph.D.

    Chief Executive Officer

    3 Sugar Creek Ctr. Blvd.
    Suite 525

    Sugar Land, Texas 77478

    (713) 489-8654

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Divakar Gupta

    Madison A. Jones

    Cooley LLP

    55 Hudson Yards

    New York, NY 10001

    (212) 479-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated Filer ¨
    Non-accelerated filer x Smaller reporting company x
         Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Tvardi Therapeutics, Inc. (the “Registrant”) for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans are effective. The Registrant previously registered its shares of common stock, par value $0.001 per share (the “Common Stock”), for issuance under the Registrant’s 2025 Equity Incentive Plan and the Registrant’s 2025 Employee Stock Purchase Plan under the Registrant’s Registration Statement on Form S-8 (the “Prior Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) on October 20, 2025 (File No. 333-290976). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference, except that the provisions contained in Part II of such Prior Registration Statement are modified or supplemented, as the case may be, as set forth in this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.INCORPORATION OF DOCUMENTS BY REFERENCE.

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Securities and Exchange Commission (“SEC”):

     

    (a)Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026;

     

    (b)Current Report on Form 8-K, which was filed with the SEC on March 6, 2026; and

     

    (c)the description of the Registrant’s Common Stock, which is registered under Section 12 of the Exchange Act of 1934, as amended (the “Exchange Act”), described in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026, including all amendments or reports filed for the purpose of updating such description.

     

    All documents, reports and definitive proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    ITEM 8.EXHIBITS.

     

    Exhibit
    Number
      Description
       
    4.1   Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on February 7, 2014).
       
    4.2   Certificate of Amendment to Amended and Restated Certificate of Incorporation dated June 7, 2024 (First Authorized Shares Amendment) (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on June 7, 2024).

     

     

     

     

    4.3   Certificate of Amendment to Amended and Restated Certificate of Incorporation dated December 30, 2024 (First Stock Split Amendment) (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on December 30, 2024).
         
    4.4   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., dated April 15, 2025 (Second Stock Split Amendment). (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    4.5   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., dated April 15, 2025 (Second Authorized Shares Amendment) (incorporated by reference from Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    4.6   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., dated April 15, 2025 (Name Change Amendment) (incorporated by reference from Exhibit 3.3 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    4.7   Amended and Restated Bylaws (incorporated by reference from Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-36279), filed with the SEC on November 14, 2024).
         
    5.1   Opinion of Cooley LLP.
         
    23.1   Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
         
    23.2   Consent of Cooley LLP. Reference is made to Exhibit 5.1.
         
    24.1   Power of Attorney. Reference is made to the signature page hereto.
         
    99.1   Tvardi Therapeutics, Inc. 2025 Equity Incentive Plan (incorporated by reference from Exhibit 10.14 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    99.2   Forms of Option Grant Notices, Option Agreements and Notices of Exercise under Tvardi Therapeutics, Inc. 2025 Equity Incentive Plan (incorporated by reference from Exhibit 10.15 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    99.3   Form of Restricted Stock Unit Grant Notice and Award Agreement under Tvardi Therapeutics, Inc. 2025 Equity Incentive Plan (incorporated by reference from Exhibit 10.16 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    99.4   Tvardi Therapeutics, Inc. 2025 Employee Stock Purchase Plan (incorporated by reference from Exhibit 10.17 to the Registrant’s Current Report on Form 8-K (File No. 001-36279), filed with the SEC on April 15, 2025).
         
    107   Filing Fee Table.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on April 1, 2026.

     

      TVARDI THERAPEUTICS, INC.
         
      By: /s/ Imran Alibhai, Ph.D.
        Imran Alibhai, Ph.D.
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Imran Alibhai, Ph.D. and Dan Conn, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable Tvardi Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Imran Alibhai, Ph.D.   Chief Executive Officer and Director   April 1, 2026
    Imran Alibhai, Ph.D.   (Principal Executive Officer)    
             
    /s/ Dan Conn, J.D., MBA   Chief Financial Officer   April 1, 2026
    Dan Conn, J.D., MBA   (Principal Financial Officer)    
             
    /s/ Stephen O’Brien   Vice President, Finance and Corporate Controller   April 1, 2026
    Stephen O’Brien   (Principal Accounting Officer)    
             
    /s/ Sujal Shah   Chairman   April 1, 2026
    Sujal Shah        
             
    /s/ Wallace Hall   Director   April 1, 2026
    Wallace Hall        
             
    /s/ Michael S. Wyzga   Director   April 1, 2026
    Michael S. Wyzga        
             
    /s/ Cynthia Smith   Director   April 1, 2026
    Cynthia Smith        
             
    /s/ Susan Shiff, Ph.D.   Director   April 1, 2026
    Susan Shiff, Ph.D.        

     

     

     

    Get the next $TVRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVRD

    DatePrice TargetRatingAnalyst
    10/14/2025$5.00Overweight → Equal Weight
    Barclays
    10/14/2025Outperform → Mkt Perform
    Raymond James
    10/13/2025Overweight → Neutral
    Cantor Fitzgerald
    10/13/2025$78.00 → $4.00Overweight → Neutral
    Piper Sandler
    10/13/2025$61.00Overweight
    Barclays
    7/14/2025$62.00Outperform
    Raymond James
    7/11/2025$52.00Overweight
    Cantor Fitzgerald
    6/12/2025$78.00Overweight
    Piper Sandler
    More analyst ratings

    $TVRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tvardi Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Tvardi Therapeutics from Overweight to Equal Weight and set a new price target of $5.00

    10/14/25 8:43:30 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics downgraded by Raymond James

    Raymond James downgraded Tvardi Therapeutics from Outperform to Mkt Perform

    10/14/25 8:43:20 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Tvardi Therapeutics from Overweight to Neutral

    10/13/25 10:13:22 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

    Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and prov

    3/31/26 4:01:00 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics to Participate in Upcoming Investor Conferences

    HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences: JonesTrading C-Suite Fireside Chat SeriesDate: Wednesday, February 19, 2026Time: 11:00 AM ESTRegistration Link here Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate presentationDate: Wednesday, February 25, 2026Time: 10:40 AM ESTLocation: Virtual TD Cowen 46th Annual Health Care ConferenceFormat: Corporate prese

    2/12/26 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th – 15th, 2026, in San Francisco, CA. During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmona

    1/8/26 4:05:00 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    SEC Filings

    View All

    SEC Form S-8 filed by Tvardi Therapeutics Inc.

    S-8 - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    4/1/26 6:10:39 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS EX filed by Tvardi Therapeutics Inc.

    POS EX - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    4/1/26 6:07:44 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Tvardi Therapeutics Inc.

    424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    4/1/26 6:01:20 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    2/2/26 4:30:14 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    2/2/26 4:30:16 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    2/2/26 4:30:13 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Financials

    Live finance-specific insights

    View All

    Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

    Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory

    10/13/25 7:30:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care